Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?
We congratulate Bonner and colleagues for their updated 5-year survival analysis of radiotherapy plus cetuximab for locoregionally advanced head and neck cancer.1 Regrettably, the authors have chosen not to update the primary endpoint, locoregional control, which makes it more difficult for the readers to interpret the study.